ArticleAnalytical and bioanalytical chemistry2026
Mapping the kidney distribution of Huangkui capsule-derived components in diabetic nephropathy treatment: a mass spectrometry imaging and metabolomics approach nominates quercetin and its conjugates as bioactive candidates.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Huangkui capsule (HKC) demonstrates significant efficacy against diabetic nephropathy (DN), yet its bioactive components that exert effects within the target organ, the kidney, have remained poorly characterized. This study aimed to elucidate the renal in situ effective constituents of HKC by integrating multimodal mass spectrometry analyses. A spontaneous DN model was established using db/db mice. Physiological parameters, biochemical indices, and histopathological assessments confirmed the model's success and the therapeutic effects of HKC intervention. Serum pharmacochemistry based on UPLC-Q-TOF-MS/MS characterized 24 absorbed components. Among them, quercetin, isoquercetin, and their metabolites exhibited the strongest correlation with pharmacodynamic indicators. Crucially, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-TOF-MSI) directly visualized and identified these quercetin-derived conjugates, particularly quercetin glucuronide, within kidney tissues, suggesting their potential as primary in situ bioactive candidates. This study is the first to spatially resolve the kidney distribution of HKC's active constituents, providing a scientific basis for understanding its mechanism of action and advancing quality control protocols.
Indexed as
Identifiers
41557180What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.